Kornimate/medical-research-clean huggingface dataset:
shenfu injection for myocardial protection in patients with acute st segment elevation myocardial infarction

Conditions: Myocardial Infarction

Summary: the purpose of this study is to evaluate whether perioperative use of shenfu injection could reduce myocardial injury (enzymatic infarct size and infarct volume according to cardiac magnetic resonance imaging) in patients with stemi after primary pci


Eligibility criteria:
inclusion criteria: 1. age ≥18 and \<75 years; 2. first-time acute anterior stemi; 3. the time from onset of ischemic symptom to the time of initial pci balloon inflation ≤6 hours; 4. \>0.1 mv st segment elevation in at least two contiguous precordial leads according to electrocardiogram; 5. scheduled for primary pci; 6. the presence of left anterior descending branch (lad) occlusion in proximal or middle segment with pre-pci timi flow 0 or 1 according to baseline coronary angiogram; 7. written informed consent. exclusion criteria: 1. hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis, or myocarditis; 2. cardiogenic shock, severe ventricular arrhythmia, serious heart failure (killip class iii and above) or mechanical complications; 3. patients after cardiopulmonary resuscitation (cpr) (including cardioversion); 4. patients who have already received thrombolytic therapy; 5. prior myocardial infarction or coronary artery bypass surgery; 6. known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases; 7. malignant tumor, lymphoma, hiv-positive, or hepatitis; 8. uncontrolled hypertension (systolic bp \>160 mm hg or a diastolic bp \>100 mmhg on at least two consecutive readings); 9. patients with active bleeding, major surgery or trauma within 3 months and cerebrovascular accident within 6 months; 10. history of anemia (hemoglobin\<90g/l) or thrombocytopenia (thrombocyte\<90×109/l); 11. multi-vessel disease with non-culprit vessel intervention; 12. breastfeeding, pregnant, or potentially fertile women; 13. patients who have known to be allergic to shenfu injection or its components or patients with serious adverse effect; 14. patients with potential contraindication to cmr; 15. participation in other clinical trial in recent 3 months; 16. patients who cannot complete this trial or comply with the protocol.

Keywords: shenfu injection reperfusion injury myocardial protection percutaneous coronary intervention
thrombocytopenia induced by chemotherapy

Conditions: Thrombocytopenia

Summary: single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of study product in patient with chemotherapy induced thrombocytopenia. the study is divided into \[screening visit (visit 1) \> baseline and treatment allocation visit (visit 2) \>blood collection (visit 3); treatment compliance visit (visit 4) \> blood collection (visit 5) \>blood collection (visit 6)\>end of study visit (visit 7)\].

uplat® (carica papaya leaf extract + tinospora cardifolia extract), is an orally administered dietary supplement for management of thrombocytopenia. manufactured bysanat products ltd. throughout study, it will be designated as product a to maintain study blindness at subject end. placebo throughout study, it will be designated as product b to maintain study blindness at subject end. single blind, randomized, multicentric placebo controlled study to evaluate the efficacy of study product in patient with chemotherapy induced thrombocytopenia. the study is divided into \[screening visit (visit 1) \> baseline and treatment allocation visit (visit 2) \>blood collection (visit 3); treatment compliance visit (visit 4) \> blood collection (visit 5) \>blood collection (visit 6)\>end of study visit (visit 7)\]. dose regimen after meeting the inclusion criteria subject will take 4 units daily (2 in morning and 2 in evening) for 10 days. patients will be called on day5th, 10th and 15thfor the complete blood count (central lab). total blood loss approximately 8-12 ml

Eligibility criteria:
inclusion criteria: 1. male or female aged between 18-55 years. 2. subjects must sign with date an informed consent prior to any evaluation and participation in the trial. 3. patients who were confirmed solid tumour and received at least one cycle of chemotherapy prior to screening visit. 4. patients with a platelet counts between \> 20000 and \< 150,000/ml at the time of screening. exclusion criteria: 1. planning to receive any type of surgery. 2. pregnant or lactating women. 3. patients with platelet count less than 20000/ml. 4. patients with thrombocytopenia presenting with active bleeding. 5. patients who have received blood or blood product transfusion during the current illness or during past one week. 6. patients with thrombocytopenia purpura (itp) leukemia, hemophilia or bleeding diathesis. 7. participation in another trial with another investigational product
transpulmonary pressure gradients in high frequency oscillation

Conditions: Acute Lung Injury

Summary: patients with severe lung conditions occasionally require support with a special ventilator (breathing machine) called the high frequency oscillator (hfo). effective ventilation requires that the pressure generated by the ventilator be as high as possible but not too high as this can damage the lungs. in patients on hfo, there is not a well defined way to measure this pressure. we will insert a small probe into the esophagus of patients on hfo to see if this is an accurate way to measure lung pressures for these patients. a better understanding of these pressures could lead to improved patient care.

trials have found that the use of lower tidal volumes (6 ml/kg) during conventional mechanical ventilation decreases morbidity and mortality. compared to conventional ventilation, high frequency oscillation (hfo) is able to provide much smaller tidal volumes (1.1 - 2.5 ml/kg) and thus theoretically may provide additional lung protection. at this time, while trials of hfo in adults have been inconclusive, the use of hfo for the management of ali/ards has become widespread patients with acute lung injury (ali) or acute respiratory distress syndrome (ards) are critically ill and have a high mortality associated with their illness (approximately 50%). currently, esophageal pressure monitors are used to optimize inflation pressures and improve oxygenation in conventional mechanical ventilation in patients with ali/ards. with this in mind, the purpose of this study is twofold: (1) demonstrate that esophageal pressure monitors can easily be inserted in patients undergoing hfo and (2) report the transpulmonary pressures in these patients.

Eligibility criteria:
inclusion criteria: * 19 years of age or older * receiving hfo * informed consent obtained exclusion criteria: * esophageal lesions or esophageal surgery within the last 6 months * morbid obesity - defined as a body mass index (bmi) \> 40 * unstable cervical spine injury or cervical spinal cord injury

Keywords: high frequency oscillation oscillation hfo transpulmonary pressure
yoga practice for breast or ovarian cancer patients

Conditions: Ovarian Cancer; Breast Cancer

Summary: previous research suggests that regular physical activity may make cancer survivors do better in the long run. laboratory studies suggest that stress may be bad for cancer patients as well. the investigators are interested in whether yoga, a practice that combines physical activity and stress reduction, is beneficial to cancer survivors. to answer that question, the investigators will need to do a large scale clinical trial. before the investigators can do that large study, they need to know whether people are willing to participate in this kind of study, whether they can do the yoga practice regularly and for how long, what kind of changes they may experience in how they can handle their daily activities, emotion, sleep, memory and problem solving ability, and what are the changes that can happen in their body after doing the yoga practice. answering these questions is what this study is about.


Eligibility criteria:
inclusion criteria: * woman age 18 or older * history of stage 0-iii breast cancer or stage i-iii ovarian cancer; all antitumor therapies, excluding hormonal therapy, have been completed at least 60 days prior to enrollment * ecog performance status 0-1 (within 90 days of enrollment) * sedentary: \<90 minutes/week of moderate-intensity (not exhausting, light perspiration, e.g. fast walking, tennis, easy bicycling, easy swimming, popular and folk dancing) physical activity during the preceding 2 months, and \<30 minutes/month of any high-intensity activity (heart beats rapidly, sweating, e.g. running, aerobics classes, cross country skiing, vigorous swimming, vigorous bicycling) in the past 2 months exclusion criteria: * evidence of active malignant disease * currently has breast implant (which limits the performance of many yoga poses) * significant cardiopulmonary disease, severe arthritis, glaucoma or any other medical conditions that make yoga practice unsafe as determined by a study investigator. * patient requires regular use of beta blockers or calcium channel blockers. * use of any medication that would interfere with the study's initial blood tests, including insulin or insulin secretagogues, corticosteroids, daily use of nsaids (except aspirin at no more than 81 mg/day) within 7 days of the initial study blood test. * unlikely to be compliant with the study intervention

Keywords: yoga 14-059
stockholm myocardial infarction with normal coronaries (sminc)-2 study on diagnosis made by cardiac mri

Conditions: Myocardial Infarction

Summary: myocardial infarction with angiographically normal coronary arteries (minca) is common (7-8 % of all myocardial infarctions). there are several different causes behind minca where "true infarction" due to thromboembolism, myocarditis or takotsubo stress cardiomyopathy are the main findings. the underlying diagnosis is often made by clinical findings sometimes with the help of cardiac mri (cmr). investigators have previously shown that it was possible to give 50 % of the patients a diagnosis made by the combination of clinical findings and cmr made in median 12 days after the acute event. the present study aim at improve the diagnostic accuracy by an early cmr with latest technique.

the present study aim at improve the diagnostic accuracy in minca with an cmr made 2-4 days after the acute event. the aim is to give 70 % of all patients with minca (35-70 years old) a definitive diagnosis made by cmr only. one-hundred and fifty patients will be included and compared with a similar historical sample where 50 % of the patients received a diagnosis made by a late cmr and clinical findings. the study has 80 % power to detect this 20 % absolute difference (p \<0.05).

Eligibility criteria:
inclusion criteria: * 35-70 years * fullfill the diagnosic criteria of myocardial infarction * normal coronary angiography or minor atheromatosis * sinus rythm on ecg at admission exclusion criteria: * previous myocardial infarction * known cardiomyopathy * pacemaker or claustrophobia * severe chronic obstructive lung or kidney disease * pulmonary embolism
the vmvn study: virological monitoring in viet nam

Conditions: HIV Infection; AIDS

Summary: the purpose of the study is to test the hypothesis that the addition of routine viral load testing to the standard laboratory monitoring of hiv patients on first-line antiretroviral treatment (art) in vietnam will result in better clinical outcomes for patients.

the optimal strategy for monitoring antiretroviral therapy (art) in resource-limited settings (rls) is unknown. in developed countries, routine monitoring with cd4 count and viral load (vl) testing is standard practice. in rls, however, limitations in the availability of the technology for vl testing, and in financial resources to pay for vl testing, mean that few developing countries provide vl testing as part of the routine monitoring of patients on art. instead, art is monitored primary by clinical examination with cd4 testing where available. this strategy has been endorsed by the most recent who guidelines for art (who, 2010). standard laboratory monitoring of patients on art in vietnam includes cd4 testing every 6 months, where available. in many rural areas of the country, cd4 testing is not available and only clinical monitoring is used. in this study we will test the hypothesis that routine viral monitoring every 6 months for patients on first-line art will result in significantly higher rates of virological suppression and decrease the incidence of death or new or recurrent aids-defining illnesses by 50% within three years.

Eligibility criteria:
inclusion criteria: * age \>= 18 * confirmed hiv infection * not currently taking art * meets vietnam moh criteria for art (through october 2011:cd4\<250 cells/mm3, who clinical stage iv, or who clinical stage iii with cd4\<350 cells/mm3; from november 2011: cd4\<350 cells/mm3, or who clinical stage iii or iv) * completes required vietnam moh art adherence training * signs written informed consent form exclusion criteria: * any art use within the previous 3 months * history of treatment failure on first-line art or known resistance to first-line art. * unable or unwilling to give written informed consent

Keywords: art antiretroviral treatment vietnam asia viral load
clinical evaluation of the aptima® hpv assay using the panther™ system

Conditions: Human Papilloma Virus Infection

Summary: the objective is to establish that aptima hpv assay performance on the panther system is comparable to performance on the tigris system.

the aptima hpv assay is an in vitro nucleic acid amplification test for the qualitative detection of e6/e7 viral messenger rna (mrna) from 14 high-risk types of human papillomavirus (hpv) in cervical specimens. the high-risk hpv types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. the aptima hpv assay does not discriminate between the 14 high-risk types. cervical specimens collected in thinprep pap test vials containing preservcyt® solution with commercially available collection devices (broom-type device or cytobrush/spatula combination) may be tested with the aptima hpv assay either pre- or post-pap processing. the assay is used with the tigris system and the panther system. the objective is to establish that aptima hpv assay performance on the panther system is comparable to performance on the tigris system.

Eligibility criteria:
inclusion criteria: * the sample had an aliquot with a valid positive or negative aptima hpv assay tigris system result (from testing under protocol 2007hpvascus30) * an aliquot is available and suitable for testing, and * the sample was randomly selected for inclusion. exclusion criteria: * sample integrity was compromised (eg, stored under unacceptable conditions)

Keywords: hpv
preventive effect of celecoxib on sorafenib-related hand foot syndrome, a single center, randomized controlled clinical trail

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma (hcc) is a common fatal malignant tumor, although with the popularity of health examination, most patients were diagnosed as hcc in advanced stages so far. sorafenib is currently recognized worldwide as the only effective treatment for advanced hcc. however, sorafenib need long-term medication, and will bring a series of side effects, including, hand, foot and comprehensive syndrome (hand-foot syndrome, hfs) limbs swelling, rash, peeling, pain.occurrence rate of hfs is about 21%-51%, which seriously affect patient's quality of life.besides, this side effects appeared to be dose-related.when severe hfs happened, sorafenib need to reduce dosage or discontinue administration, which could seriously affect the patient's survival. therefore, investigators designed this prospective randomized controlled study to explore preventive effect of celecoxib for sorafenib related hfs, the influence on the quality of life in patients with, and also the synergistic anti-tumor effect of celecoxib in combination with sorafenib on hcc. this study will explore horizon of improving treatment for sorafenib in patients with advanced hcc,quality of life and tumor control.


Eligibility criteria:
inclusion criteria: * 1.diagnosed with hcc according to the primary liver cancer diagnosis and treatment practices published by the ministry of health in 2011 china * 2.a karnofsky performance status (kps) score ≥70 points * 3.age between 18 and 70 years * 4.child-pugh classa or b (class b patients had scores no greater than 7 points). in addition, the baseline laboratory tests had to meet the following criteria: white blood cells (wbcs) ≥1.5 × 109/l, platelets ≥50 × 109/l, hemoglobin ≥80 g/l, serum aspartate transaminase (ast) and alanine transaminase (alt) ≤ 2 x the upper limit of normal (uln), serum creatinine ≤ 1.5 x uln, an international normalized ratio (inr)\<1.5 or prothrombin time \< the uln + 4 seconds, albumin ≥30 g/l, and total bilirubin ≤34mmol/l * 5.patients with advanced hepatocellular carcinoma who failed first-line therapy with surgery，radiofrequency ablation exclusion criteria: * 1.pugh child-pugh grade c, or with massive ascites or had a history of hepatic encephalopathy, or previous history of gastrointestinal bleeding * 2.poor general condition or cachexia

Keywords: hepatocellular carcinoma sorafenib celecoxib
a study to evaluate autologous cik cells in patients with hepatocellular carcinoma after tace, peit or rfa

Conditions: Hepatocellular Carcinoma

Summary: a phase i/ii, open label study to evaluate the safety and efficacy of autologous cytokine-induced killer (cik) cell for patients with hepatocellular carcinoma (hcc) after transarterial chemoembolization (tace), percutaneous ethanol injection therapy (peit) or radiofrequency ablation (rfa) therapy.


Eligibility criteria:
inclusion criteria: 1. 20 to 80 years old men and women; 2. hcc diagnosed with typical imaging findings, or confirmed by needle liver biopsy; 3. patients who are not a transplant candidate; 4. patients who have no extrahepatic metastasis and are with measurable residual tumor after tace, peit or rfa therapy; 5. patients who have a life expectancy of at least 6 months; 6. child-pugh class should be a or b; 7. eastern cooperative oncology group (ecog) performance status score was 0-3; 8. patients who have clinical laboratory test results as follows: * absolute neutrophil count ≥ 1,500/µl or white blood cell ≥ 4,000/µl * hemoglobin ≥ 8.5 g/dl * platelet count ≥ 50,000/µl * blood creatinine ≤ 1.5 x upper limit of normal * total bilirubin \< 3 x upper limit of normal * albumin ≥ 2.8 g/dl * international normalized ratio (inr) / partial thromboplastin time (ptt) \< 1.5 x upper limit of normal 9. written informed consent. exclusion criteria: 1. patients who have infiltrative or diffuse hcc; 2. patients who have significant cardiovascular disease such as myocardial infarction occurred within recent 6 months, chronic heart failure or unstable coronary artery disease; 3. patients who plan to receive systemic chemotherapy or target therapy; 4. patients with other malignant tumor within the past 5 years before treatment; 5. pregnant or lactating patients; 6. patients with hemorrhage/bleeding event; 7. patients with uncontrolled infections; 8. known or suspected allergy to the investigational agent or any agent given in association with this trial; 9. patients who have current human immunodeficiency virus (hiv) or treponema pallidum (tp) infection; 10. patients who are suffering from serious autoimmune disease; 11. patients who have had long term use of or are using an immunosuppressant; 12. history of organ transplant; 13. prior use of any anti-cancer treatments within 30 days or 5 half-lives (whichever is longer), except tace, peit and rfa therapy; 14. patients who have participated in another clinical study and received treatment within 30 days prior to the screening visit; 15. mental conditions rendering the patient incapable of understanding the nature, scope, and consequences of the study; 16. other situations that the researchers considered unsuitable for this study.

Keywords: hepatocellular carcinoma, autologous cytokine-induced killer
influence of the nebulizer on the clinical efficacy of hypertonic saline 3% in children aged less than 18 months and hospitalized with acute viral bronchiolitis

Conditions: Acute Viral Bronchiolitis

Summary: the aim of the investigators study is to compare in children aged less than 18 months and hospitalized for an acute viral bronchiolitis the efficacy of the hs 3% (mucoclear®, sterile ampoules of 4 ml) nebulised with a conventional jet-nebulizer (particles diameter of 4-5 µm), or with a jet-nebulizer adapted for infants (particles diameter of 2-2.5 µm), or with a mesh-nebulizer adapted for infants (particles diameter of 2-2.5 µm).


Eligibility criteria:
inclusion criteria: * infant of less than 18 months old * infant hospitalized for a 1st episode of bronchiolitis defined as a 1st episode of respiratory difficulty with sibilant and\\or crépitants in a viral context (head cold and\\or cough and\\or fever and\\or notion of contage) * necessity of an clinical score upper to 4. this clinical score, described by wang in 1992, is the clinical score classically used in the studies concerning the acute(sharp) bronchiolitis of the infant ( 8,9,12 ). he(it) is at most on 12 points. * absence of respiratory décompensation requiring an admission in unity of pediatric intensive care * signature of the informed consent * membership in a national insurance exclusion criteria: * refusal of the parents to participate in the study * 18-month-old infant hospitalized for acute(sharp) bronchiolitis with a clinical score lower than 4. * signs of respiratory décompensation requiring a transfer in resuscitation, signs of hypercapnie or episodes of apneas * histories of bronchiolitis or asthma of the infant * cardiac underlying pathology, respiratory, neuromuscular, immunodeficient or former premature of less of 34 weeks of amenorrhoea and less than 3 months of corrected age. * child having set within 6 hours preceding the inclusion a treatment by bronchodilatateurs or corticoids by systematic or inhaled way.